NIH

NIH-funded trial to determine if immunomodulation can improve brain and cardiovascular dysfunction in Long COVID

Vanderbilt University Medical Center is working with scientists around the U.S. to launch the first Phase III, multicenter, placebo-controlled trial to determine the effect of immunomodulation on Long COVID.

A biomarker for early Type 2 diabetes

Genetic analyses suggest that branched chain amino acids may be a sensitive biomarker of early or subclinical Type 2 diabetes and could be used to identify risk and implement preventive measures.

Data haul improves immunotherapy response prediction

Vanderbilt biostatisticians have developed an immunotherapy response model that outperforms existing predictive models.

Team uses COVID-19 to test automated acute disease profiling

An automated solution for creating phenotyping algorithms, PheNorm, worked well to identify symptomatic COVID-19 cases in electronic health records, suggesting that automation could speed high-throughput phenotyping of acute disease.

Glucose metabolism influences B cell function

Glucose metabolism influences the qualities of activated, mature B cells — white blood cells that are required for antibody-mediated immune responses, Vanderbilt researchers discovered.

Study examines social factors and cardiovascular disease risk

Eight social factors were among the top 15 markers of cardiovascular disease risk and could help guide community prevention efforts, according to a new study using machine learning algorithms.

1 2 3 104